Dandelion Health’s Post

Unpacking the Clinical Efficacy of Dapagliflozin in Heart Failure Patients with Deteriorating Renal Function 🔍 📊 #DataScience #HealthcareAnalytics #ClinicalTrials #HeartFailure 📝 Introduction: A recent pooled analysis of the DAPA-HF and DELIVER trials explored the implications of using Dapagliflozin in patients with heart failure (HF) who also experience a decline in estimated Glomerular Filtration Rate (eGFR), a key metric for kidney function. 📈 Key Methodology: Study Design: Double-blind, placebo-controlled randomized trials. Clinical Endpoints: Time to first worsening HF event or cardiovascular death. Statistical Analysis: Time-updated Cox proportional hazard models. 📌 Major Findings: Incidence: About 3.2% of the total 11,007 randomized patients experienced an eGFR deterioration below 25 mL/min/1.73 m^2. Cardiovascular Outcomes: Those with eGFR < 25 mL/min/1.73 m^2 had nearly double the incidence of the primary composite outcome compared to those without such deterioration. Efficacy of Dapagliflozin: Regardless of eGFR decline, dapagliflozin treatment was associated with lower rates of the primary composite outcome. Safety: No significant difference in adverse events between dapagliflozin and placebo groups, even for those with deteriorated kidney function. 📚 Analytical Insights: Risk Stratification: Patients experiencing an eGFR decline are at heightened risk, indicating a need for more aggressive therapeutic strategies. Absolute Risk Reduction: Treatment with dapagliflozin resulted in higher absolute risk reduction among patients with deteriorated kidney function. 🌐 Implications for Data-Driven Healthcare: These findings support the idea that the benefit-to-risk ratio may favor continuing treatment with dapagliflozin, even in patients with HF and declining eGFR. This is crucial for data-driven therapeutic decisions in complex clinical scenarios involving comorbidities like HF and CKD. Stay tuned for #HealthEconomics Analysis of #Dapagliflozin in HF Patients with Deteriorating Renal Function on the next post. Leave your questions and comments bellow.

Weight loss treatment for COVID-19 in patients with NCDs: a pilot prospective clinical trial Weight Loss Treatment for COVID-19 in Patients with NCDs: A Pilot Prospective Clinical Trial Practical Solutions and Value Highlights The study evaluated the effects of a restricted diet on inflammation, metabolic profile, and body composition in COVID-19 patients with noncommunicable chronic diseases (NCDs). This included type 2 diabetes (T2D), hypertension, or nonalcoholic steatohepatitis (NASH). Interventions involved a restricted diet with calorie restriction, hot water drinking, walking, and sexual self-restraint. Key Findings In the main group, patients with overweight experienced a significant weight loss. Body temperature and C-reactive protein decreased significantly compared to the control group. There were also favorable impacts on blood pressure, glucose/lipid metabolism, liver function, and chest CT results in the main group at 14 days of treatment. Value of the Treatment The rapid weight loss treatment showed potential benefits for COVID-19 patients with comorbid NCDs over traditional medical treatment, as it improved clinical and laboratory data, allowed patients to discontinue previous medications, and positively impacted various health parameters. Importance of Clinical Trials Clinical trials are crucial for developing safe and effective treatments and should be integrated into everyday medical practice. Find out more about how DocSym, our AI-driven platform, consolidates clinical knowledge and standards, and how our mobile apps support healthcare operations and patient care at aidevmd.com. https://lnkd.in/et_8cpQq #ClinicalTrials #AIinHealthcare #MedicalAI #HealthTech #DigitalHealth #PatientCareAI #AIResearch #MedicalInnovation #BioTech #AIforGood #HealthcareData #AIinMedicine #PharmaAI #ClinicalData #HealthAI #AIHealthSolutions #PrecisionMedicine #AIandHealth #ClinicalAnalytics #AIDiagnostics

https://lnkd.in/dxuU3b9k Interesting: Summary is that it’s good for patients clinically, but drives incremental costs in the short term. With respect to hypertension costs, that is.

A must read; value of the clinical lab managing a Clinical Lab 2.0 proactive ‘Lab Initiated Care Model’ of CKD prevalent in collaboration with National Kidney Foundation. A retrospective, non-experimental, non-interventional study was conducted at 3 health care organizations to identify clinical gaps in care for patients with stage 3 or 4 chronic kidney disease (CKD), and financial opportunity from risk adjustment payment systems. Lack of evaluation for CKD in patients with diabetes was also assessed. Methods: Outpatient longitudinal laboratory results and patient metadata available in the electronic medical record, laboratory information system, and/or laboratory billing or facility claims data for the calendar year 2021 were evaluated. Laboratory results were compared to billing data (ICD-10 codes) and risk adjustment scores including Hierarchical Condition Categories (HCCs) to determine if laboratory-identified CKD was coded as a disease condition in the electronic medical record. Adults 18 to 75 years of age were included; inpatient laboratory results and pregnant women were excluded.

The treatment market for urea cycle disorders is experiencing remarkable growth, driven by various factors that are shaping its trajectory. Increased awareness and education about these disorders have led to early diagnosis and timely treatment initiation, significantly improving patient outcomes. Advancements in newborn screening technologies have further enhanced early detection capabilities, facilitating prompt interventions. Moreover, the emergence of patient support networks has provided invaluable resources to both patients and caregivers, contributing to better disease management. The establishment of standardized treatment protocols has also played a crucial role in improving care practices and enhancing patient outcomes. Looking ahead, the forecasted growth in the urea cycle disorders treatment market is promising. Anticipated advancements in enzyme replacement therapy hold potential for revolutionizing treatment approaches, offering improved efficacy and patient outcomes. Additionally, the expansion of newborn screening programs and increased research collaboration are expected to drive early intervention and facilitate the development of novel therapies. As the market continues to evolve, innovation, collaboration, and patient-centric approaches will remain key drivers of progress. Exciting times lie ahead as we navigate challenges and seize opportunities to unlock the full potential of this burgeoning market. https://lnkd.in/gqjUYnM9 #UreaCycleDisorders #HealthcareInnovation #PatientCare

Thanks to MedPage Today for bringing the attention of physicians to our case report. https://lnkd.in/eKx_GZp8 With over 4 million monthly visitors, the MedPage Today newspaper reaches over two-thirds of all US physicians. Although most cases of anti-amyloid therapies are asymptomatic or mild to moderate, physicians must be aware of such severe cases to better recognize and manage them outside of clinical trial settings.   In addition to physicians, who may have already seen or will encounter ARIA in their clinical practice, I hope that the case report draws the attention of patients. While physicians ensure patients make well-informed decisions when weighing the potential therapeutic benefits, knowing what the worst-case scenario may actually look like provides additional depth to statistical risks.

📃Scientific paper: Comparison of 30-Day Outcomes after Carotid Artery Stenting in Patients with Near-Occlusion and Severe Stenosis: A Propensity Score Matching Analysis Abstract: BACKGROUND AND PURPOSE: Carotid artery near-occlusion is a type of severe stenosis with complete or partial distal luminal collapse and intracranial collaterals. This study aimed to compare 30-day outcomes and 10-year survival in patients undergoing carotid artery stenting for near-occlusion with a control group of patients with severe stenosis. MATERIALS AND METHODS: We used data from a registry of 639 patients who underwent 789 carotid artery stenting procedures between 2005 and 2021. The primary end point was any stroke or death within 30 days after carotid artery stenting. Patients were matched using propensity scores based on 6 variables. RESULTS: Propensity score matching yielded 84 subjects in the near-occlusion group matched with 168 subjects in the control group. In the matched cohort, the primary end point occurred in 7 (8.3%) and 11 (6.6%) patients in the near-occlusion and control groups, respectively (P = .611). In the unmatched cohort, the primary end point occurred in 7 (8.3%) and 19 (4.1%) patients (P = .101). Survival in the near-occlusion group versus the control group in the matched cohort at 5 and 10 years was 69.8% (95% CI, 58.0%–78.8%) versus 77.3% (95% CI, 70.0%–83.1%) and 53.3% (95% CI, 39.9%–65.0%) versus 53.3% (95% CI, 44.5%–61.4%) (log-rank, P = .798). CONCLUSIONS: Carotid stent placement in patients with ICA near-occlusion was not associated with an increased 30-day risk of stroke or death compared with severe stenosis. Survival up to 1... Continued on ES/IODE ➡️ https://etcse.fr/KOWk ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

Learn more about how the Spatz adjustable gastric balloon achieves a fivefold greater weight loss than control in our pivotal clinical trial published in the Lancet. Spatz Balloon patients exhibited a remarkable 15% reduction in initial weight, in contrast to the 3% weight loss seen with lifestyle intervention alone. For more details, read the full study below 👇. #ObesityTreatment #GastricBalloon #ClinicalTrial #WeightLoss

How effective is the Spatz3? This is a common question we often get asked. As a clinician in the field, building rigorous clinical evidence is paramount for a successful medical device that offers the public a safe and effective treatment. If you have not had a chance to read our pivotal clinical study published in the peer-reviewed leading journal, the Lancet, please take a look. The study was a prospective, multicentre, open-label, randomized clinical trial done at seven US sites. Adults aged 22–65 years with obesity were randomly assigned (2:1) to the Spatz Medical adjustable intragastric balloon (aIGB) with lifestyle intervention or lifestyle intervention alone (control) for 32 weeks. Key results: A fivefold greater weight loss with the Spatz Balloon (aIGB group) with a significant mean total body weight loss of 15%, compared to 3.3% in the control group. Clinical response was observed in 92% of patients in the aIGB group. The study was performed using rigorous methodologies, including an open-label, intention-to-treat, randomized design. As described in the paper, "The adjustability of this IGB could have facilitated the considerably greater efficacy observed compared with that of other non-adjustable balloons." This excellent efficacy profile of the Spatz3 was also reaffirmed in our FDA Post Approval Study. Read the study here, and if you would like to know more, please do reach out to me > https://lnkd.in/d7B6WeQi #ObesityTreatment #GastricBalloon #ClinicalTrial #WeightLoss

Please find our latest publication on Diabetes Care😊: Assessing the Associations Between Postdischarge Care and Cognitive Impairment-Related Hospital Readmissions for Ketoacidosis and Severe Hypoglycemia. Cognitive impairment adds readmission risk to patients previously admitted due to ketoacidosis or hypoglycemia. Postdischarge care mitigates the extra risk, emphasizing its role in complex comorbid diabetes and CI cases. Article highlights ·      Why did we undertake this study? o  Evidence lacks about whether postdischarge care (PDC) can mitigate the escalated risk of readmission among patients with diabetes and cognitive impairment (CI) due to compromised self-care. ·      What is the specific question(s) we wanted to answer? o  Does PDC mitigate the excessive readmission risk associated with CI among diabetes patients admitted due to hypoglycemia and ketoacidosis? ·      What did we find? o  Using the National Readmission Database, we found CI increased readmission risk in people with diabetes admitted for hypoglycemia and ketoacidosis cohorts. However, among patients discharged with PDC, PDC negated this excessive readmission CI-related risk. ·      What are the implications of our findings? o  PDC is crucial in reducing elevated readmission risks in patients with co-morbid diabetes and CI.